Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
IPO Year: 2015
Exchange: NASDAQ
Website: lantheus.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/18/2024 | $143.00 | Buy | Goldman |
| 9/3/2024 | $175.00 | Buy | Redburn Atlantic |
| 7/10/2024 | $100.00 → $130.00 | Mkt Outperform | JMP Securities |
| 12/18/2023 | Outperform → Mkt Perform | William Blair | |
| 12/4/2023 | $100.00 | Outperform | TD Cowen |
| 9/29/2023 | Outperform | William Blair | |
| 3/8/2023 | $120.00 | Mkt Outperform | JMP Securities |
| 11/30/2022 | Outperform | SVB Leerink | |
| 10/13/2022 | $105.00 | Buy | Mizuho |
| 5/9/2022 | $91.00 | Buy | B. Riley Securities |
SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
10-Q - Lantheus Holdings, Inc. (0001521036) (Filer)
8-K - Lantheus Holdings, Inc. (0001521036) (Filer)
8-K - Lantheus Holdings, Inc. (0001521036) (Filer)
8-K - Lantheus Holdings, Inc. (0001521036) (Filer)
DEFA14A - Lantheus Holdings, Inc. (0001521036) (Filer)
DEF 14A - Lantheus Holdings, Inc. (0001521036) (Filer)
10-K - Lantheus Holdings, Inc. (0001521036) (Filer)
8-K - Lantheus Holdings, Inc. (0001521036) (Filer)
SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
Worldwide revenue of $372.8 million in the first quarter 2025GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024Free cash flow totaled $98.8 million for the first quarter 2025Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition of Life Molecular Imaging in the coming weeks; and yesterday announced planned divestiture of SPECT businessRecently announced positive data for two MK-6240 pivotal studies; plan to file NDA in the third quarter of 2025Provided updated interim corporate guidance for full year
Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite® BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced a definitive agreement to sell its single photon emission computed tomography (SPECT) business to Illuminated Holdings, Inc., the parent company of SHINE Technologies, LLC (collectively, "SHINE"). Under the terms of
BEDFORD, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that its clinical-stage F18-labeled tau Positron Emission Tomography (PET) radiodiagnostic, MK-6240 (F18-florquinitau), successfully met its co-primary endpoints in two pivotal studies assessing its sensitivity and specificity. This achievement reinforces the potential of MK-6240 as a valuable diagnostic tool. The data from these two studies will support a New Drug Application (NDA) submission to the U.S. Food and Drug Admin
BEDFORD, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to discuss its financial and operating results for the first quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days. About Lan
BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has completed its previously announced acquisition of Evergreen Theragnostics, Inc. ("Evergreen"), a clinical-stage radiopharmaceutical company. The acquisition was first announced on January 28, 2025. Through the transaction, Lantheus has acquired OCTEVY™, a registrational-stage PET diagnostic imaging agent targeting neuroendocrine tumors, which complements Lantheus' therapeutic candidate PNT2003,
Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024GAAP fully diluted loss per share of $(0.17) and earnings per share of $4.36 for the fourth quarter and full year 2024Adjusted fully diluted earnings per share of $1.59 and $6.76 for the fourth quarter and full year 2024PYLARIFY exceeds $1 billion in net sales and becomes first ever blockbuster radiodiagnosticCompany announces a series of strategic asset and in-licensing deals that is expected to diversify its portfolio with early- to late-stage assets that position the company for continued growth in high
BEDFORD, Mass., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced members of its management team will present at the following upcoming investor conferences. B. Riley Securities Precision Oncology & Radiopharma Day in New York on February 28TD Cowen 45th Annual Health Care Conference in Boston on March 4 at 2:30 pm ETLeerink Global Healthcare Conference 2025 in Miami on March 11 at 1:40 pm ET A live webcast will be available for the TD Cowen 45th Annual Health Care Conference and Leerink
BEDFORD, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025, to discuss its financial and operating results for the fourth quarter and full year of 2024. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least
Data highlights PYLARIFY's ability to detect recurrent prostate cancer in patients with low PSA Real-world evidence of PYLARIFY's effectiveness in prostate cancer being presented BEDFORD, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced piflufolastat F 18 data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place February 13-15, 2025, in San Francisco, CA.
BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors ("Board"), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record i
Goldman initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $143.00
Redburn Atlantic initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $175.00
JMP Securities reiterated coverage of Lantheus Holdings with a rating of Mkt Outperform and set a new price target of $130.00 from $100.00 previously
William Blair downgraded Lantheus Holdings from Outperform to Mkt Perform
TD Cowen initiated coverage of Lantheus Holdings with a rating of Outperform and set a new price target of $100.00
William Blair initiated coverage of Lantheus Holdings with a rating of Outperform
JMP Securities initiated coverage of Lantheus Holdings with a rating of Mkt Outperform and set a new price target of $120.00
SVB Leerink initiated coverage of Lantheus Holdings with a rating of Outperform
Mizuho initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $105.00
B. Riley Securities initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $91.00
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Reporting)
SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)
SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)
SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
SC 13D - Lantheus Holdings, Inc. (0001521036) (Filed by)
SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
Worldwide revenue of $372.8 million in the first quarter 2025GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024Free cash flow totaled $98.8 million for the first quarter 2025Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition of Life Molecular Imaging in the coming weeks; and yesterday announced planned divestiture of SPECT businessRecently announced positive data for two MK-6240 pivotal studies; plan to file NDA in the third quarter of 2025Provided updated interim corporate guidance for full year
BEDFORD, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to discuss its financial and operating results for the first quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days. About Lan
Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024GAAP fully diluted loss per share of $(0.17) and earnings per share of $4.36 for the fourth quarter and full year 2024Adjusted fully diluted earnings per share of $1.59 and $6.76 for the fourth quarter and full year 2024PYLARIFY exceeds $1 billion in net sales and becomes first ever blockbuster radiodiagnosticCompany announces a series of strategic asset and in-licensing deals that is expected to diversify its portfolio with early- to late-stage assets that position the company for continued growth in high
BEDFORD, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025, to discuss its financial and operating results for the fourth quarter and full year of 2024. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least
Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus' therapeutic agent, PNT2003 Expands oncology radiopharmaceutical pipeline with multiple clinical and pre-clinical theranostic pairs Company reaffirms Full-Year and Fourth Quarter, 2024 financial guidance Company to host conference call on January 28, 2025, at 8:30 AM ET BEDFORD, Mass., Jan. 28, 2025 /PRNewswire/ -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company c
Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus' therapeutic agent, PNT2003 Expands oncology radiopharmaceutical pipeline with multiple clinical and pre-clinical theranostic pairs Company reaffirms Full-Year and Fourth Quarter, 2024 financial guidance Company to host conference call on January 28, 2025, at 8:30 AM ET BEDFORD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focuse
Enhances Lantheus' growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease Advances Lantheus' radiopharmaceutical leadership with addition of Alzheimer's radiodiagnostic commercial infrastructure, expanded pipeline, and enhanced R&D capabilities Transaction expected to be accretive to adjusted EPS within the first 12 months Company to host conference call on January 13, 2025, at 8:30 AM EST BEDFORD, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling cli
Worldwide revenue of $378.7 million, an increase of 18.4% from third quarter 2023GAAP fully diluted earnings per share of $1.79, compared to $1.88 in the third quarter of 2023. Adjusted fully diluted earnings per share of $1.70 compared to $1.47 in the third quarter of 2023Company narrows full year 2024 revenue and fully diluted earnings per share guidance towards higher end of the previously issued guidanceCompany applauds CMS' CY25 rule to improve payment for specialized diagnostic radiopharmaceuticals, including PYLARIFY, advancing patient access and careCompany announced that it expanded its Alzheimer's disease radiodiagnostics portfolio with NAV-4694, a novel, next generation late-stage
BEDFORD, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2024, to discuss its financial and operating results for the third quarter of 2024. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days. About
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023Completed three strategic transactions to expand innovative pipelineGAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.54 in the second quarter 2023, reflective of inter-quarter investment in business development and R&D.The Company maintains full year 2024 revenue guidance and updates fully diluted earnings per share guidance driven by strategic transactions BEDFORD, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ:LNTH), the
BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors ("Board"), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record i
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors ("Board"), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent. "We are thrilled to welcome Julie Eastland t
BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Jamie Spaeth to its Executive Team as Chief People Officer. "We're excited to have Jamie join Lantheus as we continue to harness our team's potential to deliver innovative solutions to serve patients and healthcare professionals," said Dan Niedzwiecki, Chief Administrative Officer of Lantheus. "At Lantheus, our people drive our success, and Jamie's proven leadership and expertise will foster a collaborativ
Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective March 1, 2024 Mary Anne Heino to Retire as Chief Executive Officer and Become Chair of the Board of Directors BEDFORD, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the Company has appointed Brian Markison, current Board Chair and industry veteran, to the position of Chief Executive Officer (CEO), effective as of March 1, 2024. He will also contin
NORTH BILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced the appointment of Amanda Morgan as Senior Vice President, Commercial. Ms. Morgan will report to Paul Blanchfield, Lantheus' Chief Operating Officer, and will be responsible for leading all of the Company's commercial activities, including Sales, Marketing, and Market Access. "I am pleased to welcome Amanda to Lantheus," said Paul Blanchfield. "Amanda has strong commercial experti
NORTH BILLERICA, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced the appointment of Jean-Claude Provost, MD, as Interim Chief Medical Officer, effective immediately. "We have worked closely with Jean-Claude on numerous development programs over the past three years, and I am delighted to welcome him to Lantheus in an expanded role as our Interim Chief Medical Officer," said Mary Anne Heino, President and CEO, Lantheus
NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an
NORTH BILLERICA, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced the appointment of Vivian Yao to its Executive Team as Lantheus' Chief Human Resources Officer. Ms. Yao will report directly to Lantheus' President and Chief Executive Officer, Mary Anne Heino. In this role, Ms. Yao will oversee all aspects of Lantheus' employee and workplace experience, including ensuring best-in-class talent processes, people operations, total
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced that Michael P. Duffy, Senior Vice President, Law and Public Policy and General Counsel will retire from Lantheus on June 4, 2021 after more than 13 years with Lantheus. Mr. Duffy will be retained in an advisory capacity. His responsibilities will be assumed by Daniel Niedzwiecki, who has been with the Company since 2013 and will report directly to Mary Anne Heino, President and